Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.56 |
| ▸ | EGFR | P00533 | 9/20 | 0.52 |
| ▸ | ITK | Q08881 | 6/20 | 0.52 |
| ▸ | BRD4 | O60885 | 2/20 | 0.52 |
| ▸ | BTK | Q06187 | 3/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9923768 | 1.00 | SYK (0.56) | SYKEGFRITKBRD4BTK | |
| SCHEMBL4180112 | 0.90 | SYK (0.57) | SYKEGFRBRD4BTKJAK3 | |
| SCHEMBL29537421 | 0.88 | SYK (0.55) | SYKEGFRITKBRD4CDK1 | |
| SCHEMBL19533541 | 0.88 | SYK (0.55) | SYKEGFRITKBRD4CDK1 | |
| SCHEMBL29537952 | 0.88 | SYK (0.55) | SYKEGFRITKBRD4BTK | |
| SCHEMBL4166343 | 0.88 | SYK (0.55) | SYKEGFRITKBRD4BTK | |
| SCHEMBL12518613 | 0.88 | SYK (0.71) | SYKEGFRITKBRD4MET | |
| SCHEMBL24393210 | 0.87 | SYK (0.54) | SYKEGFRITKBRD4BTK | |
| SCHEMBL29538047 | 0.87 | SYK (0.54) | SYKEGFRITKBRD4BTK | |
| SCHEMBL13669998 | 0.86 | EGFR (0.46) | SYKEGFRITKBRD4BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | SYK 3137/4885EGFR 452/4885ITK 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.